Connexin 40 Mediates the Tubuloglomerular Feedback Contribution to Renal Blood Flow Autoregulation

Armin Just,*† Lisa Kurtz,‡ Cor de Wit,§ Charlotte Wagner,‖ Armin Kurtz,‖ and William J. Arendshorst*†¶

*Department of Cell & Molecular Physiology, †Carolina Cardiovascular Biology Center, and ‡University of North Carolina Kidney Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; §Physiologisches Institut der Universität Regensburg, Regensburg, Germany; and ‖Physiologisches Institut der Universität Lübeck, Lübeck, Germany; ‡Klinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany

ABSTRACT
Connexins are important in vascular development and function. Connexin 40 (Cx40), which plays a predominant role in the formation of gap junctions in the vasculature, participates in the autoregulation of renal blood flow (RBF), but the underlying mechanisms are unknown. Here, Cx40-deficient mice (Cx40-ko) had impaired steady-state autoregulation to a sudden step increase in renal perfusion pressure. Analysis of the mechanisms underlying this derangement suggested that a marked reduction in tubuloglomerular feedback (TGF) in Cx40-ko mice was responsible. In transgenic mice with Cx40 replaced by Cx45, steady-state autoregulation and TGF were weaker than those in wild-type mice but stronger than those in Cx40-ko mice. N•Nitro-L-arginine-methyl-ester (L-NAME) augmented the myogenic response similarly in all genotypes, leaving autoregulation impaired in transgenic animals. The responses of renovascular resistance and arterial pressure to norepinephrine and acetylcholine were similar in all groups before or after L-NAME inhibition. Systemic and renal vasoconstrictor responses to L-NAME were also similar in all genotypes. We conclude that Cx40 contributes to RBF autoregulation by transducing TGF-mediated signals to the afferent arteriole, a function that is independent of nitric oxide (NO). However, Cx40 is not required for the modulation of the renal myogenic response by NO, norepinephrine-induced renal vasoconstriction, and acetylcholine- or NO-induced vasodilation.

technically localized for impacting GFR, tubuloglomerular feedback (TGF), and renin secretion. Indeed, deletion of Cx40 leads to increased production of renin, ectopic renin expression, and loss of pressure- and angiotensin II (Ang II)-dependent control of renin release.6,7,13 A rise in plasma renin concentration is also seen after administration of a putative Cx40-inhibiting peptide.12 However, Cx40 expression is increased in response to a chronic reduction of renal perfusion pressure, a common stimulus for renin synthesis.10

Our knowledge of the role of Cx40 in the regulation of organ blood flow and vascular resistance in vivo is limited. In the kidney, intrarenal infusion of peptides designed to inhibit Cx37, Cx40, or both Cx40 and Cx43 reduces basal renal blood flow (RBF) and increases AP.12,14 Steady-state autoregulation of RBF and GFR is reported to be partially inhibited by peptides directed against Cx37 or Cx40.12 Not known, however, is which of the three mechanisms responsible for renal autoregulation (TGF, myogenic response (MR), and an undefined third mechanism15,16) is affected. In isolated JGAs, TGF responses17 and associated calcium waves18 are inhibited by nonspecific pharmacologic gap junction disrupters (e.g., heptanol). Such interventions also attenuate the MR to changes in vascular pressure in isolated cerebral and mesenteric arteries,20 as is the case for inhibitory peptides against Cx37 and Cx43.20 However, the functional significance of genetic deletion of Cx40 for blood flow regulation and autoregulation in vivo in any vascular bed, including the kidney, is not known. We postulated that Cx40 is required for complete autoregulation and TGF activity.

Also poorly understood is the importance of gap junctions in vivo in vasoconstrictor and vasodilator responses of resistance arterioles. α-Adrenergically induced vasoconstriction is blunted by pharmacologic gap junction inhibitors in isolated arteries.20,21 Gap junctions are also implicated in vasodilation,14,22 although it is unclear whether or not Cx40 is involved.3,14,23 Few studies have tested the participation of connexins in vasodilation in vivo.5,14 To our knowledge, no data exist regarding connexins in vasoconstrictor responses in an animal.

Nitric oxide (NO) may interact with connexin function. NO is thought to modulate connexin conductance acutely24 and expression chronically.25 NO attenuates the magnitude of acute vasoconstriction elicited by receptor agonists such as Ang II and NE.26 In addition, NO blunts the strength of the pressure-induced MR in RBF autoregulation, an effect specific to the kidney and dependent on JGA function and TGF.27,28 Considering the possible involvement of Cx40 in JGA function, we postulated that Cx40 is critical for NO modulation of agonist-induced renal vascular responses and pressure-induced RBF autoregulation.

The present study tested the hypotheses that (a) Cx40 is essential to RBF autoregulation and is involved in MR, TGF, or

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean AP (mmHg)</th>
<th>RBF (ml min⁻¹ g KW⁻¹)</th>
<th>HR (min⁻¹)</th>
<th>UV (µl min⁻¹)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type control</td>
<td>85 ± 5</td>
<td>7.3 ± 1.2</td>
<td>523 ± 32</td>
<td>11 ± 2</td>
<td>6</td>
</tr>
<tr>
<td>Cx40-ko control</td>
<td>100 ± 5</td>
<td>6.7 ± 1.3</td>
<td>533 ± 22</td>
<td>13 ± 3</td>
<td>6</td>
</tr>
<tr>
<td>Cx40KI45 control</td>
<td>96 ± 6</td>
<td>9.1 ± 0.9</td>
<td>539 ± 27</td>
<td>18 ± 2</td>
<td>5</td>
</tr>
<tr>
<td>Wild-type L-NAME</td>
<td>122 ± 4ª</td>
<td>4.1 ± 0.5b</td>
<td>416 ± 47</td>
<td>11 ± 3</td>
<td>4</td>
</tr>
<tr>
<td>Cx40-ko L-NAME</td>
<td>123 ± 7</td>
<td>4.1 ± 1.1b</td>
<td>415 ± 9b</td>
<td>19 ± 1</td>
<td>4</td>
</tr>
<tr>
<td>Cx40KI45 L-NAME</td>
<td>121 ± 8b</td>
<td>5.8 ± 0.5b</td>
<td>482 ± 24</td>
<td>18 ± 2</td>
<td>4</td>
</tr>
</tbody>
</table>

*HR, heart rate; KW, kidney weight; UV, bilateral urine flow rate. Mean ± SEM. P<0.05 and P<0.001 versus the paired control before L-NAME inhibition in the same animal (paired t test).
both responses to an acute change in renal perfusion pressure, (b) Cx40 contributes to agonist-induced vasodilator and constrictor responses in the renal and systemic circulation, and (c) Cx40 is involved in the signaling pathway of NO that blunts the renal MR. To this end, we conducted RBF studies on mice with genetic ablation of Cx40. Parallel studies were performed on mice with the coding region for Cx40 replaced by Cx45 regulated by the Cx40 promotor. In the latter, we postulated that Cx45 can assume Cx40 function, at least in part.

RESULTS

Hemodynamics

Cx40-deficient mice (Cx40-ko) mice had higher AP than those of wild-type (wt) controls (Table 1), as reported previously5–7 Cx40KI45 animals tended to have an intermediate level of AP (Table 1). Baseline RBF, heart rate, and urine flow rate were similar among groups (Table 1).

Figure 1 shows the time course of the autoregulatory response of renal vascular resistance (RVR) to a sudden step increase in renal artery pressure (RAP). In wt mice, RVR initially fell and then quickly rose within 5 to 7 s. A secondary rise in RVR occurred between approximately 7 and approximately 30 s. In a third phase, RVR slowly approached the final level over the following 90 s. According to the literature and our previous analyses, the first phase of RVR rise most likely reflects the MR, the secondary rise the TGF (probably together with a “fourth” mechanism), and the tertiary phase a “third” mechanism distinct from classical TGF and the MR.16 The strength and contribution of these components are assessed from RVR increases in the time windows from approximately 1 to approximately 5 s for the MR, from approximately 5 to approximately 25 s for TGF, and between approximately 25 and approximately 100 s for the third mechanism. On the basis of this analysis in wt mice, the MR provided an autoregulatory gain of 22%, TGF (and fourth mechanism) of 75%, and the third mechanism of 27% (Table 2). Overall steady-state autoregulation, apparent from the stable level reached between 90 to 120 s was very efficient (102%, Table 2). The sum of the contributions of individual mechanisms exceeds 100% because the MR is calculated from the initial minimum RVR, whereas steady-state efficiency is determined from the RVR level before the RAP increase.

Cx40-ko mice had severely impaired steady-state RBF autoregulation in response to a step increase in renal arterial pressure (RVR) compared to controls (Table 2). In Cx40-ko mice, the myogenic response (initial 7 s) was significantly reduced compared to controls, while the TGF and fourth mechanism remained intact. Cx40KI45 animals had intermediate values, suggesting that Cx45 can partially compensate for the absence of Cx40. L-NAME, a nitric oxide synthase inhibitor, further impaired RBF autoregulation in all groups, with the greatest effect in Cx40-ko mice. Figure 2 shows the strength of TGF and the fourth regulatory mechanism in wt, Cx40-ko, and Cx40KI45 mice. Figure 3 compares the effect of L-NAME on RBF autoregulation in wt and Cx40-ko mice.
toregulation (24 versus 102%, Figure 1 and Table 2). This was primarily due to attenuation of the second component (5 to 25 s) involving TGF (Figures 1 and 2 and Table 2). The MR and the third mechanism were essentially normal in Cx40-ko mice (Figures 1 and 3 and Table 2). Note that the nadir of RVR during the first second was lower in Cx40-ko than that in wt mice (−37 ± 6 versus −22 ± 4%, P > 0.08). The contribution of MR in Cx40-ko animals (Table 2) was therefore larger than it may appear from the level of autoregulation at 4 to 7 s in the time course (Figure 1). Replacement of the coding region for Cx40 by Cx45 (Cx40KI45) partially improved autoregulation as well as the strength of the TGF-related autoregulatory component (Figures 1 and 2). Nevertheless, both measures remained significantly less than those in wt mice (Figures 1 and 2 and Table 2). MR and the third mechanism in Cx40KI45 mice did not differ from those in wt animals (Figures 1 and 3 and Table 2).

The acute renal vasoconstrictor response to NE and the vasodilation to acetylcholine (ACh) were virtually identical in Cx40-ko and wt mice (Figure 4 and Table 3). The effects of NE and ACh on RBF were also normal in Cx40KI45 mice (Figure 4 and Table 3). Likewise, there were no differences between genotypes in the systemic AP responses to ACh (Table 3). Thus, integrated renal vascular smooth muscle function was undisturbed by either the absence of Cx40 or replacement with Cx45.

Acute nitric oxide synthase (NOS) inhibition by Nω-nitro-L-arginine-methyl-ester (L-NAME) increased AP (+27 to 40%, P > 0.1 between genotypes) and reduced RBF (−39 to 41%, P > 0.7) similarly in all genotypes (Table 1). L-NAME augmented the strength of the MR without affecting steady-state autoregulatory efficiency in each group, thereby shifting the contribution of mechanisms toward the most rapid MR (Table 2). Overall autoregulation remained less efficient in Cx40-ko compared with wt and tended to persist at an intermediate level in Cx40KI45 during NOS inhibition (Table 2). The MR was increased to a similar degree in all genotypes (Figures 1 and 3 and Table 2).

As a comparison for the overall dynamic response to a single step increase in AP, classical staircase steady-state autoregulation curves were also performed. During L-NAME inhibition, RBF autoregulation was near perfect in wt mice down to an 82% reduction (Table 2). Replacement of the coding region for Cx40 by Cx45 (Cx40KI45) partially improved autoregulation (24% versus 102% at 60 s, P < 0.001) and RBF autoregulation (25% versus 40% at 60 s, P < 0.001) above Cx40-ko (Figure 1 and Table 2).

Table 3. Cardiovascular responses to bolus injections of NE and ACh

<table>
<thead>
<tr>
<th>Group</th>
<th>AP Change from Baseline</th>
<th>RBF Change from Baseline</th>
<th>RVR Change from Baseline</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NE</td>
<td>RBF</td>
<td>RVR</td>
<td></td>
</tr>
<tr>
<td>Wild-type control</td>
<td>+49 ± 3</td>
<td>−53 ± 8</td>
<td>+275 ± 60</td>
<td>5</td>
</tr>
<tr>
<td>Cx40-ko control</td>
<td>+28 ± 2 b</td>
<td>−61 ± 1</td>
<td>+255 ± 13</td>
<td>4</td>
</tr>
<tr>
<td>Cx40KI45 control</td>
<td>+48 ± 7</td>
<td>−46 ± 9</td>
<td>+207 ± 49</td>
<td>4</td>
</tr>
<tr>
<td>Wild-type L-NAME</td>
<td>+24 ± 4 d</td>
<td>−82 ± 6</td>
<td>+6741 ± 5594 c</td>
<td>4</td>
</tr>
<tr>
<td>Cx40-ko L-NAME</td>
<td>+29 ± 3</td>
<td>−78 ± 2 e</td>
<td>+581 ± 61 e</td>
<td>4</td>
</tr>
<tr>
<td>Cx40KI45 L-NAME</td>
<td>+27 ± 4</td>
<td>−67 ± 5</td>
<td>+328 ± 65</td>
<td>4</td>
</tr>
</tbody>
</table>

*Mean ± SEM. **P < 0.05, ***P < 0.01, and ****P < 0.001 versus the paired control before L-NAME in the same animal (paired t test). **P < 0.05 versus respective wild-type. SEM is high because in one animal RBF almost ceased in response to NE during L-NAME, resulting in a very large resistance value.
proximately 70 mmHg (Figure 5). In Cx40-ko animals, autoregulation was markedly impaired as indicated by the absence of a plateau and steadily increasing RBF with AP (Figure 5). Autoregulatory efficiencies over a range of approximately 20 mmHg below the resting level of AP were 104% (114 and 94%) in wt and 50% in Cx40-ko mice, values similar to autoregulation in the dynamic step responses during L-NAME inhibition (Table 2).

L-NAME tended to enhance renal vasoconstrictor responses to NE in all groups (Table 3), although it differed statistically only in Cx40-ko. ACh-induced renal vasodilation was not affected by L-NAME in wt and Cx40KI45 mice and was slightly augmented in Cx40-ko (Table 3). AP responses to NE tended to be smaller during L-NAME inhibition in all genotypes. ACh-induced reductions in AP were not affected by L-NAME (P > 0.1). Differences between genotypes were not detected during L-NAME inhibition in the RBF or systemic AP responses to either NE or ACh (Table 3).

**Histology**

In the JGA of wt kidneys, preglomerular endothelial, renin-producing, and extraglomerular mesangial cells expressed Cx37 (Figure 6E), Cx40 (Figure 6A), and Cx43 (Figure 6H), whereas Cx45 was restricted to vascular smooth muscle cells (Figure 6B). Within glomeruli, Cx37 was found in proximity to the vascular pole (Figure 6E). Cx40 and Cx43 showed prominent expression in presumable mesangial cells (Figure 6, A and H). Cx45 staining was seen in more peripheral cells, presumably podocytes (Figure 6B).

In the JGA of Cx40-deficient kidneys, Cx40 was absent, and expression of Cx37 and Cx43 was clearly reduced in glomerular and mesangial regions (Figure 6, F and I). Cx37 was also severely diminished along the afferent arteriolar endothelium (Figure 6F). The expression pattern of Cx45 was not appreciably altered in the absence of Cx40 (Figure 6D). In Cx40KI45 kidneys, Cx45 appeared in the endothelium of preglomerular vessels, in the renin-producing cells, and in extra- and intraglomerular mesangial cells (Figure 6C). The reduced Cx37 and Cx43 expression in Cx40 deficient kidneys, however, was not reversed in Cx40KI45 mice (Figure 6, G and J).

**DISCUSSION**

The present study demonstrates that RBF autoregulation is markedly impaired in mice lacking Cx40. This defect is primarily due to blunting of the TGF component, with normal contributions of the MR and the third mechanism. Thus, Cx40 in the JGA appears to be critical for transduction of a TGF-mediated vasoconstrictor signal to afferent arterioles participating in autoregulation. In contrast, integrated responses of renovascular resistance and systemic AP to NE, ACh, and NO remain intact. These novel in vivo observations indicate that there is no major defect in vasoconstrictor, endothelium-de-
dependent, or NO-mediated vasodilator properties of renal or systemic resistance arterioles lacking Cx40. Thus, the autoregulatory deficiency in Cx40 null mice is not due to a general malfunction of renal vasomotor responses. Cx45 expressed in place of Cx40 partly substitutes the function of Cx40 in TGF and renal hemodynamics. Despite the role of Cx40 in the TGF component of RBF autoregulation, the known TGF-dependent influence of NO on the renal MR does not require Cx40.

Impaired RBF autoregulation is documented both in the single step dynamic response and in the classical staircase steady-state autoregulation curve. Dynamic responses indicate that the secondary phase (between approximately 5 and approximately 25 s) is affected most markedly in mice lacking Cx40. This component has been shown to reflect the action of classical TGF in dogs, rats, and mice. The present data therefore indicate that classical TGF is severely attenuated in the absence of Cx40. The 5 to 25 s time window also includes a fourth regulatory mechanism distinct from classical TGF that is resistant to furosemide and independent of A1 adenosine receptors (A1ARs). The present results thus do not allow a definitive conclusion about the extent to which the fourth mechanism is affected by Cx40. However, because the degree of impairment of the 5 to 25 s component of Cx40-k0 mice is similar to that found during complete TGF inhibition by furosemide or genetic ablation of A1AR, it is reasonable to conclude that TGF is absent in Cx40-k0 mice. Because the renal vasomotor responses to NE, ACh, and NOS inhibition do not differ between genotypes, the observed defect in autoregulation and TGF is not due to a general dysfunction of renal vasomotor responsiveness. Our findings, using a specific genetic approach, extend those of a previous pharmacologic report of impaired autoregulation of RBF and GFR during infusion of a putative inhibitory peptide against Cx40. Importantly, our new data identify TGF as the primary target of the function of Cx40 in RBF autoregulation.

The mechanism by which Cx40 contributes to TGF-mediated autoregulation is not clear. A commonly accepted pathway of TGF signaling is that macula densa cells release ATP upon stimulation by elevated tubular NaCl concentration. The released ATP may be degraded by extracellular nucleotidases in the JGA to adenosine, which then can constrict afferent arterioles via A1AR. Alternatively or in addition, ATP may contract afferent arterioles by activating purinergic P2X receptors. Given the high prevalence of gap junctions in the JGA, the signal transduction of TGF might also follow a transcellular route from the macula densa through extraglomerular mesangial cells to the afferent arteriole. Recent studies showed mesangial propagation of TGF-induced calcium waves from the macula densa to glomerular and arteriolar sites. Because mesangial cells express several P2 receptors, they may be activated by ATP released from the macula densa. Whether Cx40 primarily serves to connect mesangial cells, smooth muscle cells, or both or acts as hemichannel to release further ATP from mesangial cells, as observed in cell culture, warrants further investigation.

In contrast, the myogenic component of the autoregulatory response is not different in Cx40-deficient and wt kidneys. Thus, concluding that Cx40 is not required for the MR in the kidney seems reasonable. Although this may seem surprising given the involvement of Cx40 in conducted responses, a pressure step likely reaches all parts of the vascular tree almost simultaneously. Responses to such uniform mechanical stimulation may not require conducted responses along the preglomerular vasculature. Moreover, Cx40 deficiency impairs only conduction of vasodilator but not vasoconstrictor signals.

Replacement of Cx40 by Cx45, regulated by the Cx40 promoter, improves the defects in autoregulation and TGF but does not completely restore them to normal. The reason why Cx45 only partially replaces the function of Cx40 in the JGA is not known. Apart from the lower permeability of Cx45, other features (secondary structure, voltage gating, signaling, and interactions with scaffolding proteins or microtubules) might be essential for the formation of heterotypic gap junctions, appropriate clustering, or regulation of their permeability. The cellular distribution of Cx45 in Cx40K145 mice mirrors the normal pattern of Cx40, and expression of Cx37 and Cx43 is similar in Cx40K145 to that in Cx40-k0 kidneys. Although Cx40 is essential for signal transduction from the macula densa to the afferent arteriole in TGF-mediated vasoregulation, macula densa-mediated regulation of renin release seems to be appropriate in Cx40-k0 mice during changes in salt intake or inhibition of macula densa sensor function by loop diuretics. The same comparisons are obtained for A1AR-deficient mice, in which TGF is absent and yet loop diuretic stimulation of renin release is preserved. These observations suggest that two signaling pathways may emanate from the macula densa, one involving Cx40 and A1AR controlling TGF and a separate one regulating renin release.

Little is known about the contribution of Cx40 to agonist-induced vasomotor responses in vivo. Our results indicate that neither vasoconstrictor, nor endothelium-dependent, nor NO-mediated vasodilator responses in the intact mouse kidney are affected by the absence of Cx40. Similar results are found for AP responses, suggesting that Cx40 does not contribute to these vasodilator responses in most nonrenal vascular beds. Our results confirm previous findings on the lack of Cx40 involvement in systemic depressor responses to ACh and extend them to vasodilator and vasoconstrictor responses in the kidney. These findings do not contrast with participation of Cx40 in conducted vasodilator responses initiated locally at a specific site, because stimulation by systemic application of these substances likely activates all sites along the vascular tree almost simultaneously. The vasomotor responsiveness to Ang II remains open. However, abnormal sensitivity to Ang II would unlikely have altered the conclusion that deficiency of Cx40 impairs RBF autoregulation, because steady-state autoregulation is usually not affected by Ang II infusion, angiotensin converting enzyme (ACE) inhibition, AT1 receptor antagonism, or chronic changes in sodium diet.
We and others have shown that NO exerts a strong attenuating influence on the MR in the renal but not nonrenal circulations. Importantly, this NO influence depends on functional TGF, suggesting neuronal NOS in macula densa cells as the source. Given the probable role of Cx40 in TGF signal transduction and the possibility of NO modulation of connexin conductance, we postulated that the absence of Cx40 impacts on NO effects on the renal MR. This, however, was not the case, because inhibition of NO production has similar augmenting effects on the MR in wt, Cx40-ko, and Cx40KI45 mice. Nevertheless, our current observations extend the prevalence of NO-mediated blunting of the renal MR from rats to mice, extending its relevance to additional species. To the extent that the NO responsible for this effect derives from neuronal NOS in macula densa cells, our data imply that Cx40 is not required for such NO to act on the afferent arteriole.

**Perspectives**

Impaired RBF autoregulation, particularly in combination with hypertension, is known to predispose to pressure-induced damage of the kidney. Because Cx40-deficient mice have elevated AP, compromised RBF autoregulation might render them prone to accelerated glomerular sclerosis. Central to an in-depth understanding of TGF function is knowledge of which particular signals are normally transduced through Cx40 in the JGA. Future investigations are warranted to understand the importance of Cx40 and autoregulation in protecting against glomerular injury and the underlying signaling pathways of the TGF-dependent influence of NO on the MR in the renal microcirculation. It is tempting to speculate that alterations in connexin-dependent pathways might be altered in diseases associated with hyperfiltration or accelerated glomerular sclerosis.

**CONCISE METHODS**

Experiments were conducted on seven gene-targeted mice deficient for Cx40 (Cx40-ko, age 17 to 34 wks, body wt 25 to 29 g, left kidney wt 0.18 to 0.26 g, 5 males + 2 females) and 6 wt controls of the C57BL6 strain (wt, 9 to 34 wks, 18 to 27 g, left kidney wt 0.13 to 0.19 g, 4 males + 2 females). In addition, hemodynamics were studied in five mice from a strain in which the coding region of Cx40 had been replaced biallelically by Cx45 (Cx40KI45, 17 to 45 wks, 24 to 38 g, left kidney wt 0.19 to 0.36 g, 4 males + 1 female). Wild-type and gene-targeted mice (backcrossed for 10 generations into a C57BL6 genetic background) were bred and genotyped at the University of Lübeck. Four wt mice were purchased from Charles River, Germany. All experiments were conducted at the University of Regensburg, Germany, in accordance with German animal protection law and with the Institute of Laboratory Animal Resources (ILAR) Guide for the Care and Use of Laboratory Animals. Animals were fed a standard lab chow with free access to tap water on a 12 h:12 h light−dark cycle.

Immunohistochemistry for Cx37, Cx40, Cx43, and Cx45 was done on 5-µm cryosections as described previously. Renin antibody (chicken anti-mouse) was generated by Davids Biotechnologie, Regensburg, Germany. Anti-Cx40 (goat anti-mouse, Santa Cruz, Santa Cruz, CA), anti-Cx37 (rabbit anti-mouse, Alpha Diagnostic International, San Antonio, TX), anti-Cx43 (rabbit anti-mouse, Sigma, St. Louis, MO), and anti-Cx45 (rabbit anti-mouse) were purchased.

For hemodynamic studies, anesthesia (pentobarbital), surgery, experimental procedures, and data analysis were similar to previous reports. An albumin solution (2.38 g dl−1, 12 µl min−1) was infused intravenously. Injected into jugular vein catheters were the vasoactive agents (NE (3 mg ml−1) and Ach (1 mg ml−1) mixed in saline). Arterial pressure in a catheterized femoral artery was measured using a pressure transducer (ADInstruments, Bella Vista, NSW, Australia). A mechanical occluder was placed on the aorta. A flowprobe (0.5 PSB, Transonic) was positioned around the left renal artery to measure RBF by an ultrasound transit-time flowmeter (TS-420, Transonic, low-pass filter 40 Hz; Transonic, Ithaca, NY). All data were recorded on a computer at 100 Hz (LabChart Pro, ADInstruments).

The autoregulatory response of RBF to a rapid step increase in RAP within the autoregulatory pressure range was investigated as described previously. Baseline values for Cx40 and the MR, autoregulation step responses were assessed every 5 min after injection of the NOS inhibitor L-NAME (25 mg/kg intravenously, 4 to 6 step responses). Subsequently, NE and ACh were infused as described in protocol A. In some animals (2 male wt and 5 male Cx40-ko) classical staircase steady-state autoregulation curves were assessed by reducing RAP in a sequential step-wise fashion in 10 mmHg decrements, keeping each level stable for 100 s. Steady-state results were calculated from RBF and RAP during the final 30 s of each pressure level.

**Data Analysis**

RBP, RBF, and RVR data were analyzed as described previously. Baseline values given in Table 2 were obtained from the 10 s before each RAP reduction during a particular experimental period. First and second derivatives of RVR were calculated from the time courses of RVR by applying the Savitzky–Golay algorithm with a window size of 11 points and coefficients for third-order fitting. Autoregulatory efficiency is expressed as percentage of perfect autoregulation as described previously. The transition between the initial (MR) and the secondary response (TGF) was determined from the slowest RVR change within the first 10 s after the RAP step. This was obtained from the time of zero-crossing of the second derivative.

**Protocol A: Baseline Conditions**

NE (75 µg in 25 µl) and ACh (25 µg in 25 µl), were injected intravenously over <2 s, separated by 5 min. Another 5 min later, RAP steps were induced every 5 min. Multiple responses were recorded in each experimental period.

**Protocol B: NOS Inhibition**

To test whether the effect of Cx40 deficiency is due to possible overproduction of NO and whether Cx40 is involved in the effects of NO on baseline RBF and the MR, autoregulation step responses were assessed 15 min after injection of the NOS inhibitor L-NAME (25 mg/kg intravenously, 4 to 6 step responses). Subsequently, NE and ACh were injected as described in protocol A. In some animals (2 male wt and 5 male Cx40-ko) classical staircase steady-state autoregulation curves were assessed by reducing RAP in a sequential step-wise fashion in 10 mmHg decrements, keeping each level stable for 100 s. Steady-state results were calculated from RBF and RAP during the final 30 s of each pressure level.
of RVR.16 The zero-crossing was found at 6.8 ± 0.8 s in wt, 7.4 ± 0.4 s in Cx40-ko, and 7.3 ± 1.2 s in Cx40KI45. The regulatory strength of each mechanism was derived from the improvement of autoregulatory efficiency within specified time intervals after the pressure step.16 The MR was estimated from the autoregulatory change in RVR between t0 = 0 s and t1 = 4 to 7 s after the pressure step, TGF from t2 = 4 to 7 s to t3 = 20 to 30 s, and the third mechanism from t3 = 20 to 30 s to t5 = 90 to 120 s.

Statistical Analysis

Statistical significance was tested by ANOVA for repeated measures in conjunction with Holm–Sidak or Tukey post hoc test (SigmaStat 3.5, SPSS Inc., Chicago, IL). In the case of a non-normal distribution, Tukey test for multiple comparisons was used as a post hoc test. For drug effects within the same animal, a paired t test was used. A P value < 0.05 was considered statistically significant. Data are presented as mean ± SEM. The numbers of animals are indicated as n.

ACKNOWLEDGMENTS

This work was supported by the German Research Foundation through Sonderforschungsbereich 699 to A.K. and C.W. and Einzelantrag W12071/2-1 to C.D.W. and the National Heart Blood and Lung Institute, National Institutes of Health, through research grant R01 HL002334 to W.J.A. The work was conducted, analyzed, and written while A.J. was affiliated with the laboratory of W.J.A., Department of Cell and Molecular Physiology, University of North Carolina at Chapel Hill. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

DISCLOSURES

None.

REFERENCES

connections in relation to the baroreceptor reflex arc. Prog Brain Res 47: 9–34, 1977

Supplemental information for this article is available online at http://www.jasn.org/.